Phase IBII Study of Targeted Treatments and Immunotherapy With Atezolizumab for Women With Recurrent or Persistent Endometrial Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of targeted treatments, with or without the immune therapy drug atezolizumab, in women with recurrent or persistent endometrial cancer. This Phase IBII study uses genetic testing of tumor samples to assign participants to different groups based on specific tumor markers. The study aims to better understand how these targeted agents work in combination with or without immunotherapy and to identify the best treatment options for specific tumor profiles. Participants will first provide tumor tissue for genomic testing using the FoundationOne companion diagnostic. Based on the tumors genetic features, participants will be placed into specific study groups receiving targeted drugs alone or combined with atezolizumab. Treatments include various intravenous and oral drugs administered in cycles of 21 or 28 days. Each group enrolls about 20 to 24 participants and can be closed or expanded depending on results. The study also allows for additional groups to be added over time. During the study, participants will receive regular treatments and be monitored for tumor response, survival, and disease progression over several months. Researchers will assess overall response rates and the duration participants remain free from disease progression. Safety and side effects will also be closely monitored. Participants may have tumor scans, blood tests, and other evaluations to track the study drugs effects. The total follow-up period for outcomes like survival is up to 48 months, ensuring long-term observation of treatment impact.

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer